These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38829766)

  • 1. Prognosis and diagnosis of prostate cancer based on hypergraph regularization sparse least partial squares regression algorithm.
    Huang RH; Ge ZL; Xu G; Zeng QM; Jiang B; Xiao GC; Xia W; Wu YT; Liao YF
    Aging (Albany NY); 2024 May; 16(11):9599-9624. PubMed ID: 38829766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis and prognosis potential of four gene promoter hypermethylation in prostate cancer.
    Li Y; Meng L; Shi T; Ren J; Deng Q
    Cell Biol Int; 2021 Jan; 45(1):117-126. PubMed ID: 32991011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of metastasis-related genes for predicting prostate cancer diagnosis, metastasis and immunotherapy drug candidates using machine learning approaches.
    Wang Y; Ji B; Zhang L; Wang J; He J; Ding B; Ren M
    Biol Direct; 2024 Jun; 19(1):50. PubMed ID: 38918844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Random forest-based modelling to detect biomarkers for prostate cancer progression.
    Toth R; Schiffmann H; Hube-Magg C; Büscheck F; Höflmayer D; Weidemann S; Lebok P; Fraune C; Minner S; Schlomm T; Sauter G; Plass C; Assenov Y; Simon R; Meiners J; Gerhäuser C
    Clin Epigenetics; 2019 Oct; 11(1):148. PubMed ID: 31640781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Large-scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levels.
    Haldrup C; Lynnerup AS; Storebjerg TM; Vang S; Wild P; Visakorpi T; Arsov C; Schulz WA; Lindberg J; Grönberg H; Egevad L; Borre M; Ørntoft TF; Høyer S; Sørensen KD
    Mol Oncol; 2016 Jun; 10(6):825-37. PubMed ID: 26905753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ZNF154 is a promising diagnosis biomarker and predicts biochemical recurrence in prostate cancer.
    Zhang W; Shu P; Wang S; Song J; Liu K; Wang C; Ran L
    Gene; 2018 Oct; 675():136-143. PubMed ID: 29966681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Prognostic Biomarkers Associated with Cancer Stem Cell Features in Prostate Adenocarcinoma.
    Zhang D; Zhang M; Zhang Q; Zhao Z; Nie Y
    Med Sci Monit; 2020 Jul; 26():e924543. PubMed ID: 32735556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Machine Learning Method for Predicting Biomarkers Associated with Prostate Cancer.
    Tong Y; Tan Z; Wang P; Gao X
    Front Biosci (Landmark Ed); 2023 Dec; 28(12):333. PubMed ID: 38179769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coexpression Network Analysis Identifies a Novel Nine-RNA Signature to Improve Prognostic Prediction for Prostate Cancer Patients.
    Cai J; Chen Z; Chen X; Huang H; Lin X; Miao B
    Biomed Res Int; 2020; 2020():4264291. PubMed ID: 32953881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patients.
    Moreira-Barbosa C; Barros-Silva D; Costa-Pinheiro P; Torres-Ferreira J; Constâncio V; Freitas R; Oliveira J; Antunes L; Henrique R; Jerónimo C
    Clin Epigenetics; 2018 Oct; 10(1):132. PubMed ID: 30373654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenome-wide DNA methylation and transcriptome profiling of localized and locally advanced prostate cancer: Uncovering new molecular markers.
    Liu Q; Reed M; Zhu H; Cheng Y; Almeida J; Fruhbeck G; Ribeiro R; Hu P
    Genomics; 2022 Sep; 114(5):110474. PubMed ID: 36057424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylation and transcriptome analysis reveal lung adenocarcinoma-specific diagnostic biomarkers.
    Li R; Yang YE; Yin YH; Zhang MY; Li H; Qu YQ
    J Transl Med; 2019 Sep; 17(1):324. PubMed ID: 31558162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of potential prognostic biomarkers in metastatic prostate cancer based on a circular RNA-mediated competing endogenous RNA regulatory network.
    Luo L; Zhang LL; Tao W; Xia TL; Li LY
    PLoS One; 2021; 16(12):e0260983. PubMed ID: 34860853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis.
    Nørgaard M; Haldrup C; Storebjerg TM; Vestergaard EM; Wild PJ; Høyer S; Borre M; Ørntoft TF; Sørensen KD
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28930171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients.
    Meller S; Zipfel L; Gevensleben H; Dietrich J; Ellinger J; Majores M; Stein J; Sailer V; Jung M; Kristiansen G; Dietrich D
    Epigenetics; 2016 Dec; 11(12):871-880. PubMed ID: 27689475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
    BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A DNA methylation profile of long non-coding RNAs can predict OS in prostate cancer.
    Cheng W; Cao J; Xia Y; Lei X; Wu L; Shi L
    Bioengineered; 2021 Dec; 12(1):3252-3262. PubMed ID: 34238128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Solute carrier family 16 member 5 downregulation and its methylation might serve as a prognostic indicator of prostate cancer.
    Meng X; Yuan H; Li W; Xiong Z; Dong W; Xiao W; Zhang X
    IUBMB Life; 2021 Nov; 73(11):1363-1377. PubMed ID: 34549875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic syndrome-related prognostic index: Predicting biochemical recurrence and differentiating between cold and hot tumors in prostate cancer.
    Ren C; Wang Q; Wang S; Zhou H; Xu M; Li H; Li Y; Chen X; Liu X
    Front Endocrinol (Lausanne); 2023; 14():1148117. PubMed ID: 37033267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a novel six autophagy-related genes signature for the prognostic and a miRNA-related autophagy predictor for anti-PD-1 therapy responses in prostate cancer.
    Wu L; Quan W; Yue G; Luo Q; Peng D; Pan Y; Zhang G
    BMC Cancer; 2021 Jan; 21(1):15. PubMed ID: 33402116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.